Tibolone [[7alpha,17alpha]-17-hydroxy-7-methyl-19-norpregn-5(10)-en-20-yn-3-one] is used to treat climacteric symptoms and prevent osteoporosis. It exerts tissue-selective effects via site-specific metabolism into 3alpha- and 3beta-hydroxymetabolites and a Delta4-isomer. Recombinant human cytosolic aldo-keto reductases 1C1 and 1C2 (AKR1C1 and AKR1C2) produce 3beta-hydroxytibolone, and the liver...

background: tibolone is frequently used as a hormone-like alternative to traditional hrt. therefore, it is valuable to compare the effects of tibolone and hrt on cardiovascular diseases risk factors.   methods: a total of 156 healthy non-surgical postmenopausal women were included in an open randomized study. they were assigned to receive daily 2.5 mg tibolone plus one cal+d (500 mg calcium and...

OBJECTIVE More than 50% of all fractures occur in people without osteoporosis. Hormone therapy increases bone density, improves postural balance, and reduces fracture risk in postmenopausal women. It is unclear whether tibolone, a synthetic steroid hormone drug, can improve muscle strength. Thus, the aim of this study was to study the effects of low-dose tibolone therapy on muscle strength in o...

OBJECTIVE To assess the effect of tibolone treatment on the intima-media thickness (IMT) of the common carotid artery (CCA) and the resistive indices (RIs) of the CCA and internal (ICA) and external (ECA) carotid and the vertebral arteries (VAs) in postmenopausal women as sonographic markers of atherosclerosis. DESIGN A prospective study. SETTING University hospital. PATIENT(S) Twenty pos...

Health technology The study assessed a 3-year treatment course of tibolone, a synthetic steroid that has estrogenic, progestogenic and androgenic properties, in the management of postmenopausal women with climacteric symptoms. Tibolone was taken daily at a dose of 2.5 mg and was taken orally. The treatment was compared with continuous combined hormone replacement therapy, which comprised conjug...

The aim of this study was to evaluate the effects of low-dose tibolone therapy on ovarian area, uterine volume and endometrial thickness, and define the cut-off value of endometrial thickness for curettage during uterine bleeding. We followed 619 postmenopausal women, aged 40-60 years, for two years. There were 301 subjects in the low-dose tibolone treatment group and 318 subjects in the contro...

BACKGROUND Post-menopausal hormone therapy (pHT) induces changes in both body composition and bone mineral density (BMD). METHODS In 109 post-menopausal women beginning either tibolone 2.5 mg (n=29), tibolone 1.25 mg (n=42) or estradiol 2 mg plus norethisterone acetate 1 mg (E2 + NETA) (n=38), we assessed body composition, total and regional BMD by dual energy X-ray absorptiometry, and the se...